Informações de vTv Therapeutics Inc

Mais detalhes de vTv Therapeutics Inc Empresa

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its products pipeline includes TTP399, TTP273, HPP737 and HPP593. TTP399 is an orally administered, small molecule, liver-selective glucokinase activator (GKA) in development potential oral anti-diabetic for the treatment of type I diabetes. TTP399 completed the SimpliciT-I Study, a Phase II trial in patients with type I diabetes as an add-on to insulin therapy. Its HPP737 is an orally administered, non-central nervous system (CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases. TTP273 is an orally available, small molecule glucagon-like peptide 1 (GLP-1) receptor agonist, which is focused on treating postprandial hyperglycemia in cystic fibrosis related diabetes (CFRD) patients and cystic fibrosis patients. Its products pipeline also includes Azeliragon and HPP3033.



Código da empresaVTVT

Nome da EmpresavTv Therapeutics Inc

Data de listagemJul 30, 2015

CEOMr. Paul Jai Sekhri

Número de funcionários23

Tipo de títulosOrdinary Share

Fim do ano fiscalJul 30

Endereço3980 Premier Dr

CidadeHIGH POINT

Bolsa de valoresNASDAQ Capital Market Consolidated

PaísUnited States of America

Código postal27265

Telefone13368410300

Sitehttps://vtvtherapeutics.com/

Código da empresaVTVT

Data de listagemJul 30, 2015

CEOMr. Paul Jai Sekhri

Executivos da empresa vTv Therapeutics Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Paul Jai Sekhri

Chairman of the Board, President, Chief Executive Officer

5.00K

-82.80%

Dr. Anne M. Phillips, M.D.

Independent Director

2.15K

--

Dr. Raymond Cheong, M.D., Ph.D.

Independent Director

1.83K

--

Mr. Richard S. (Rich) Nelson

Executive Vice President - Corporate Development, Director

--

Dr. Srinivas Akkaraju, M.D., Ph.D.

Independent Director

--

-100.00%

Mr. Fahed Al Marzooqi, M.D.

Independent Director

--

Mr. Burns Mcclellan

Investor Relations

--

Dr. Michael Tung, M.D.

Executive Vice President, Chief Financial Officer

--

Mr. Daniel (Dan) Spiegelman

Director

--

Nome

Nome/Posição

Posição

Ações detidas

Variação

Mr. Paul Jai Sekhri

Chairman of the Board, President, Chief Executive Officer

5.00K

-82.80%

Dr. Anne M. Phillips, M.D.

Independent Director

2.15K

--

Dr. Raymond Cheong, M.D., Ph.D.

Independent Director

1.83K

--

Mr. Richard S. (Rich) Nelson

Executive Vice President - Corporate Development, Director

--

Dr. Srinivas Akkaraju, M.D., Ph.D.

Independent Director

--

-100.00%

Mr. Fahed Al Marzooqi, M.D.

Independent Director

--

Detalhamento da receita

FY2023

Sem dados

Por RegiãoUSD

Nome

Receita

Proporção

United States

0.00

0.00%

Por Empresa

Por Região

Sem dados

Distribuição de ações

Atualizado em: sáb, 13 de set

Investidores

Tipos de investidores

Investidores

Proporção

MacAndrews & Forbes Holdings, Inc.

34.88%

Samsara BioCapital, LLC

11.95%

Trails Edge Capital Partners LP

8.83%

Fidelity Management & Research Company LLC

6.81%

Invus Public Equities LP

6.23%

Outro

31.30%

Investidores

Proporção

MacAndrews & Forbes Holdings, Inc.

34.88%

Samsara BioCapital, LLC

11.95%

Trails Edge Capital Partners LP

8.83%

Fidelity Management & Research Company LLC

6.81%

Invus Public Equities LP

6.23%

Outro

31.30%

Tipos de investidores

Investidores

Proporção

Holding Company

34.88%

Investment Advisor

24.03%

Venture Capital

11.95%

Hedge Fund

6.61%

Investment Advisor/Hedge Fund

1.09%

Individual Investor

0.63%

Outro

20.81%

Participação acionária institucional



Atualizado em: qua, 1 de out

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q3

47

1.14M

43.69%

+560.06K

2025Q2

54

1.51M

57.66%

-17.51K

2025Q1

53

1.53M

60.03%

+1.63K

2024Q4

55

1.51M

61.92%

-7.51K

2024Q3

55

1.49M

61.31%

+181.69K

2024Q2

53

1.29M

53.13%

+308.00

2024Q1

64

1.68M

72.07%

+129.32K

2023Q4

64

1.40M

68.78%

-52.49K

2023Q3

72

1.41M

69.35%

-49.61K

2023Q2

81

1.40M

81.32%

+323.67K

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

MacAndrews & Forbes Holdings, Inc.

912.98K

34.88%

--

Apr 01, 2025

Samsara BioCapital, LLC

312.78K

11.95%

+106.00K

+51.26%

Sep 22, 2025

Trails Edge Capital Partners LP

231.00K

8.83%

+231.00K

--

Aug 29, 2025

Fidelity Management & Research Company LLC

178.20K

6.81%

--

Jun 30, 2025

Invus Public Equities LP

163.00K

6.23%

+163.00K

--

Aug 29, 2025

Baker Bros. Advisors LP

148.31K

5.67%

+51.00K

+52.41%

Sep 03, 2025

The Vanguard Group, Inc.

43.17K

1.65%

+1.62K

+3.89%

Jun 30, 2025

Northern Trust Investments, Inc.

15.29K

0.58%

-339.00

-2.17%

Jun 30, 2025

Millennium Management LLC

15.04K

0.57%

+15.04K

--

Jun 30, 2025

Geode Capital Management, L.L.C.

12.87K

0.49%

+229.00

+1.81%

Jun 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: há 2 horas

Nome

Proporção

iShares Micro-Cap ETF

0.01%

iShares Core S&P Total U.S. Stock Market ETF

0%

iShares Micro-Cap ETF

Proporção0.01%

iShares Core S&P Total U.S. Stock Market ETF

Proporção0%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Tipo

Proporção

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Data

Tipo

Proporção

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1